Braveheart Investments Group PLC (LON:BRH), the fund management and strategic investment group which recently undertook two oversubscribed placings to raise investment funds has issued an update after recent share price movements and social media speculation on some of its investee companies.
The group noted that the social media speculation concerned Braveheart companies which currently have projects in association with the Aptamer Group Limited.
READ: Braveheart Investment raises a further £350,000 in its second over-subscribed placing of the week
It pointed out that Paraytec Limited, in which it has a 100% holding, is in discussions with Aptamer Group and the University of Sheffield to define a project to develop a coronavirus (COVID-19) test.
The investment firm said that, if successful, this test would enable potentially infectious individuals to be identified quickly. Such a test could be used in airports, transport hubs, healthcare environments, large workplaces and similar settings, where rapid screening of large numbers of people for presence of the virus is required.
It noted that using Paraytec’s imaging capability in partnership with aptamers from Aptamer Group which bind to the spike protein on the virus, the objective is to develop a portable test, which can generate a result in a matter of minutes from a swab provided at the test location and require no specialist skills to be operated.
With regards to Kirkstall Limited, in which it has an 80% holding, Braveheart noted that Kirkstall’s Quasi-Vivo systems are being considered by Aptamer Group to provide a possible test bed for testing of aptamer-based cancer therapeutics which they are developing.
And with regards to Sentinel Medical Limited, in which it has a 38.38% holding, Braveheart said that, as previously reported, Sentinel has a licence to use Paraytec’s imaging technology to detect bladder cancer and has ongoing trials with bladder cancer patient samples, to develop a point-of-care instrument.
It said Sentinel has submitted a grant application with University of Sheffield, Aptamer Group and the Leeds Teaching Hospitals NHS Trust, to enhance this product using aptamers.